Navigation Links
NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
Date:3/19/2008

his is part of NicOx' strategy to maximize the commercial potential and economic value of naproxcinod, as NicOx owns the global development and marketing rights to this compound. Going forward, NicOx will be looking for co-commercialization partnerships for naproxcinod, with NicOx retaining certain commercialization rights in the U.S. and selected EU markets, in order to fully exploit the drug's commercial and strategic value and to aid the Company's planned transition to a fully integrated pharmaceutical business.

James Harrison, CEO of Archimica, declared: "We are very pleased to have this opportunity to apply our expertise to the manufacturing of naproxcinod and are excited by the clear potential of this innovative product. We look forward to continuing our work with the NicOx team, and leveraging our manufacturing experience to support their timely and successful launch of naproxcinod."

NicOx is developing naproxcinod in phase 3 clinical studies, which are designed to demonstrate that it is safe, well tolerated and effective for treating the signs and symptoms of osteoarthritis, in addition to having no detrimental effect on blood pressure, in contrast to existing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The final pivotal phase 3 trials are ongoing (the 302 and 303 studies) and the filing of a New Drug Application (NDA) for naproxcinod is projected for mid-2009.

About Archimica

Archimica is a privately held pharmaceutical fine chemicals company owned by TowerBrook Capital Partners and Aisling Capital Partners. Archimica combines first-class chemical manufacturing assets, technologies and process development with a history of pharmaceutical commercialization that stretches back over 40 years. With respect to new manufacturing projects, Archimica's strategy is focused on phase 2 and phase 3 clinical trial manufacturing opportunities for New Chemical Entities (NCEs) and this partnership with NicOx on naproxcinod is an important ex
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NicOx Opens U.S. Headquarters in New Jersey
2. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
3. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. Monsanto Company Signs Share Subscription Agreement With Devgen
8. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
9. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
10. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
11. Assay Designs(TM) Announces Additions to the Leadership Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... to biotechnology firms has revealed early bottlenecks on ... the researchers suggest that better communication of basic ... to faster commercialization down the road. , Biopharmaceutical ... university laboratories and licensed to biotechnology firms. Bottlenecks ... a high failure rate. But a new study ...
(Date:8/20/2014)... , Aug. 20, 2014  Decision Resources Group finds that the ... Russia , India and ... in 2013, roughly equal to the size of the ... BRIC market will experience much faster growth as a result of ... Other key findings from Decision Resources Group,s coverage of ...
(Date:8/20/2014)... your ear could improve the health of your heart, ... of Leeds used a standard TENS machine like those ... to the tragus, the small raised flap at the ... ear canal. , The stimulation changed the influence of ... nervous signals that can drive failing hearts too hard. ...
(Date:8/19/2014)... -- Research and Markets  has announced the addition of the ... report to their offering. This report analyzes ... Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided for ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
... Reportlinker.com announces that a new market ... Animal Husbandry Equipment ... http://www.reportlinker.com/p0181483/Animal-Husbandry-Equipment-Market-in-United-States-Business-Report-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Livestock ... research of animal husbandry equipment market in ...
... DIEGO, Dec. 13, 2011  Astellas Pharma Inc. (Tokyo: 4503, ... results from an interim analysis of a Phase 2 ... (AML) were presented at the 53rd Annual Meeting of ... California.  Data were also presented from two additional posters: ...
... , Dr. Vivek Desai, MD, Hosmac ... Emeritus, Infosys Technologies Clear winner under Healthcare ... appreciation added to his hat of success at the felicitation ceremony ... Dr. Vivek Desai, Managing Director, Hosmac India Pvt. Ltd. is ...
Cached Biology Technology:Animal Husbandry Equipment Market in United States: Business Report 2011 2Animal Husbandry Equipment Market in United States: Business Report 2011 3Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 2Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 3Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 4Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 5Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 6Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 7Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 8Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011 2Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011 3
(Date:8/19/2014)... . Wind ... large amount of electricity is to be produced with renewable ... be stored during productive periods so that these fluctuations can ... adequate for the purpose. Science and industry are therefore working ... systems that used to be too expensive or unsophisticated to ...
(Date:8/19/2014)... the world, leprosy and tuberculosis live side-by-side. Worldwide ... per year, with nearly all of them occurring ... vaccine Bacille Calmette-Guerin, or BCG, provides only partial ... more potent vaccine is needed to combat both ... weapon against both diseases., In a study published ...
(Date:8/19/2014)... have identified a biomarker strongly associated with basal-like ... resistant to many types of chemotherapy. The biomarker, ... for new therapeutics designed to treat this often ... taken from The Cancer Genome Atlas, molecular biologists ... powerful computational and bioinformatics techniques to detect patterns ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... type of sperm a male produces, according to new research ... the Proceedings of the National Academy of Sciences ... sperm of many species of African cichlids. These fish have ... where females mate with many males in quick succession. ...
... certain marginalized groups including the mentally ill, the ... Latinos fare worse than others in the aftermath ... Now, a new study by ... experience greater terrorism-related fears and make more behavioral changes ...
... are killers. They strike without warning, causing ... percent of all deaths in the United States., ... associated with arrhythmias. Their findings, reported in The ... to novel arrhythmia treatments., "The current antiarrhythmic drugs ...
Cached Biology News:The more promiscuous the female, the speedier the sperm 2Disabled and other vulnerable groups more susceptible to terrorism fears 2Studies point to novel target for treating arrhythmias 2Studies point to novel target for treating arrhythmias 3
... F2α isopropyl ester (15(R)-17-phenyl trinor PGF2α ... containing both a double bond at ... group at C-15. Similar to 15(S)-latanoprost, ... a potential impurity in most commercial ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... Nop1p/Fibrillarin (monoclonal) Nop1p/Fibrillarin was ... of bakers yeast, Saccharomyces cerevisiae (accession ... for yeast viability and is localized ... of Nop1p is fibrillarin (accession P22087) ...
... bind specifically to Fc regions of many ... conjugates are commonly used as affinity adsorbents ... from serum, hybridoma ascites fluids, tissue culture ... are also commonly used to capture immune ...
Biology Products: